CA2343376A1 - Formulations de ranolazine a liberation lente - Google Patents
Formulations de ranolazine a liberation lente Download PDFInfo
- Publication number
- CA2343376A1 CA2343376A1 CA002343376A CA2343376A CA2343376A1 CA 2343376 A1 CA2343376 A1 CA 2343376A1 CA 002343376 A CA002343376 A CA 002343376A CA 2343376 A CA2343376 A CA 2343376A CA 2343376 A1 CA2343376 A1 CA 2343376A1
- Authority
- CA
- Canada
- Prior art keywords
- ranolazine
- sustained release
- release ranolazine
- aqueous media
- ranolazine formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 title abstract 6
- 229960000213 ranolazine Drugs 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 239000012736 aqueous medium Substances 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000011872 intimate mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9980498P | 1998-09-10 | 1998-09-10 | |
US60/099,804 | 1998-09-10 | ||
US09/321,522 US6303607B1 (en) | 1998-09-10 | 1999-05-27 | Method for administering a sustained release ranolanolazine formulation |
US09/321,522 | 1999-05-27 | ||
PCT/US1999/020968 WO2000013687A2 (fr) | 1998-09-10 | 1999-09-09 | Formulations de ranolazine a liberation lente |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2343376A1 true CA2343376A1 (fr) | 2000-03-16 |
CA2343376C CA2343376C (fr) | 2007-01-09 |
Family
ID=26796494
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002342390A Expired - Lifetime CA2342390C (fr) | 1998-09-10 | 1999-09-09 | Formulations de ranolazine a liberation lente |
CA002343376A Expired - Lifetime CA2343376C (fr) | 1998-09-10 | 1999-09-09 | Formulations de ranolazine a liberation lente |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002342390A Expired - Lifetime CA2342390C (fr) | 1998-09-10 | 1999-09-09 | Formulations de ranolazine a liberation lente |
Country Status (33)
Country | Link |
---|---|
US (14) | US6303607B1 (fr) |
EP (3) | EP1096937B9 (fr) |
JP (2) | JP3745621B2 (fr) |
KR (1) | KR100475759B1 (fr) |
CN (2) | CN1193757C (fr) |
AR (3) | AR022085A1 (fr) |
AT (2) | ATE285774T1 (fr) |
AU (4) | AU744071B2 (fr) |
BR (2) | BR9913626A (fr) |
CA (2) | CA2342390C (fr) |
CY (1) | CY2008020I2 (fr) |
CZ (2) | CZ301341B6 (fr) |
DE (3) | DE122008000065I1 (fr) |
DK (2) | DK1096937T3 (fr) |
ES (2) | ES2234302T3 (fr) |
FR (1) | FR09C0001I2 (fr) |
GE (1) | GEP20053420B (fr) |
HK (2) | HK1040060A1 (fr) |
HU (2) | HUP0104088A3 (fr) |
IL (6) | IL141893A0 (fr) |
LU (1) | LU91504I2 (fr) |
MX (2) | MXPA01002598A (fr) |
NL (1) | NL300371I2 (fr) |
NO (4) | NO320986B1 (fr) |
NZ (2) | NZ510384A (fr) |
PL (3) | PL196668B1 (fr) |
PT (2) | PT1109558E (fr) |
RU (2) | RU2207856C2 (fr) |
SI (2) | SI1109558T1 (fr) |
TR (2) | TR200101262T2 (fr) |
TW (1) | TWI241911B (fr) |
UA (2) | UA67793C2 (fr) |
WO (2) | WO2000013687A2 (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
KR20020075801A (ko) | 2000-02-18 | 2002-10-05 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 울혈성 심부전 치료의 부분적 지방산 산화 방지제 |
US20020052377A1 (en) * | 2000-07-21 | 2002-05-02 | Wolff Andrew A. | Method for treating angina |
AU2001211213A1 (en) * | 2000-10-20 | 2002-04-29 | Galephar M/F | Stable oral formulation containing benzimidazole derivative |
FR2830447B1 (fr) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
US8101209B2 (en) * | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
US20080109040A1 (en) * | 2002-04-04 | 2008-05-08 | Luiz Belardinelli | Method of treating arrhythmias |
WO2003084518A2 (fr) | 2002-04-09 | 2003-10-16 | Flamel Technologies | Suspension orale de microcapsules de principes actifs |
ATE407674T1 (de) * | 2002-04-09 | 2008-09-15 | Flamel Tech Sa | Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin |
US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
US20040063717A1 (en) * | 2002-05-21 | 2004-04-01 | Andrew Wolff | Method of treating diabetes |
GB0403098D0 (en) | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
MX2007008162A (es) * | 2005-01-06 | 2007-07-24 | Cv Therapeutics Inc | Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina. |
FR2886150B1 (fr) * | 2005-05-24 | 2007-08-24 | Flamel Technologies Sa | Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique |
WO2007016350A2 (fr) * | 2005-07-28 | 2007-02-08 | Supernus Pharmaceuticals, Inc. | Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees |
JP5672648B2 (ja) * | 2006-03-17 | 2015-02-18 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子、表示装置および照明装置 |
FI20060501L (fi) * | 2006-05-22 | 2007-11-23 | Biohit Oyj | Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa |
US20090312340A1 (en) * | 2007-02-13 | 2009-12-17 | Whedy Wang | Use of ranolazine for the treatment of cardiovascular diseases |
CA2678319A1 (fr) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Utilisation de la ranolazine dans le traitement des maladies microvasculaires coronaires |
US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
US20080214555A1 (en) * | 2007-02-13 | 2008-09-04 | Markus Jerling | Use of ranolazine for the treatment of cardiovascular diseases |
WO2008101012A1 (fr) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Utilisation de la ranolazine pour le traitement de maladies microvasculaires non coronariennes |
JP2010520291A (ja) * | 2007-03-07 | 2010-06-10 | コンサート ファーマシューティカルズ インコーポレイテッド | 抗狭心症化合物としての重水素化ピペラジン誘導体 |
WO2008116083A1 (fr) * | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Utilisation de ranolazine contre un taux élevé de peptide natriurétique de type b |
US20080299195A1 (en) * | 2007-05-31 | 2008-12-04 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
CN101066253B (zh) * | 2007-06-07 | 2011-01-05 | 北京本草天源药物研究院 | 一种雷诺嗪缓释片 |
AU2008266124A1 (en) * | 2007-06-13 | 2008-12-24 | Auspex Pharmaceuticals, Inc. | Substituted piperazines |
US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
US20090076018A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched ranolazine |
CN101977605A (zh) * | 2008-02-06 | 2011-02-16 | 吉利德科学股份有限公司 | 雷诺嗪治疗疼痛的用途 |
AU2010248948A1 (en) * | 2009-05-14 | 2011-12-01 | Gilead Sciences, Inc. | Ranolazine for the treatment of CNS disorders |
EP2515880B1 (fr) | 2009-05-28 | 2019-11-27 | Lupin Limited | Nouvelles compositions pharmaceutiques de ranolazine |
WO2011036677A2 (fr) | 2009-09-25 | 2011-03-31 | Lupin Limited | Composition de ranolazine à libération prolongée |
TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
TW201215392A (en) | 2010-06-16 | 2012-04-16 | Gilead Sciences Inc | Use of ranolazine for treating pulmonary hypertension |
ES2414384T3 (es) | 2011-05-11 | 2013-07-19 | Ratiopharm Gmbh | Composición de liberación modificada que comprende ranolazina |
NO3175985T3 (fr) | 2011-07-01 | 2018-04-28 | ||
CA2849505A1 (fr) | 2011-09-21 | 2013-03-28 | Gilead Sciences, Inc. | Bloqueurs des canaux sodiques reduisant la secretion de glucagon |
US20160051541A1 (en) * | 2013-04-26 | 2016-02-25 | Chanrx Corporation | Pharmaceutical compositions comprising vanoxerine and antianginal compounds, and methods of administration of the same for treating episodes of cardiac arrhythmia, maintaining normal sinus rhythm, preventing recurrence of cardiac arrhythmia, and treatment of chronic cardiac arrhythmia in mammals |
CN104758265B (zh) * | 2014-01-07 | 2019-05-17 | 四川海思科制药有限公司 | 一种雷诺嗪缓释片药物组合物及其制备方法 |
TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
TW201717919A (zh) * | 2015-07-02 | 2017-06-01 | 國際藥品股份公司 | 雷諾多重壓縮錠劑 |
WO2018001582A1 (fr) | 2016-06-30 | 2018-01-04 | Interquim, S.A. | Comprimés multiples à base de ranolazine |
AR110252A1 (es) | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |
US10898444B2 (en) * | 2017-06-01 | 2021-01-26 | Sun Pharmaceutical Industries Limited | Extended release multiparticulates of ranolazine |
CN112438955A (zh) * | 2019-08-30 | 2021-03-05 | 深圳翰宇药业股份有限公司 | 一种雷诺嗪缓释组合物及其制备方法 |
US11969424B2 (en) | 2019-12-16 | 2024-04-30 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) |
CN110898024A (zh) * | 2019-12-17 | 2020-03-24 | 卓和药业集团有限公司 | 一种治疗心绞痛的药物组合物及制备方法 |
GR1010345B (el) * | 2021-12-16 | 2022-11-28 | Φαρματεν Α.Β.Ε.Ε., | Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων |
GR1010510B (el) * | 2022-06-07 | 2023-07-20 | Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, | Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4567264A (en) | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
IL81419A0 (en) * | 1986-01-30 | 1987-08-31 | Syntex Inc | Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation |
ATE142497T1 (de) * | 1989-06-23 | 1996-09-15 | Syntex Inc | Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen |
US5527545A (en) | 1989-09-18 | 1996-06-18 | Recordati S.A. Chemical And Pharmaceutical Company | Liquid-suspension controlled-release pharmaceutical composition |
US5209933A (en) * | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
JP2516524B2 (ja) * | 1992-04-27 | 1996-07-24 | 大洋薬品工業株式会社 | 持続性製剤 |
JPH06199657A (ja) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
US5455045A (en) | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
JPH07112932A (ja) * | 1993-08-27 | 1995-05-02 | Mitsui Toatsu Chem Inc | 徐放性医薬製剤 |
US5525606A (en) * | 1994-08-01 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines |
JPH08259446A (ja) * | 1995-01-24 | 1996-10-08 | Mitsui Toatsu Chem Inc | 持効性医薬製剤 |
JPH08310946A (ja) * | 1995-05-19 | 1996-11-26 | Yuutoku Yakuhin Kogyo Kk | 経皮吸収製剤 |
JPH09188617A (ja) * | 1996-01-08 | 1997-07-22 | Pola Chem Ind Inc | 徐放性医薬組成物 |
US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
-
1999
- 1999-05-27 US US09/321,522 patent/US6303607B1/en not_active Expired - Lifetime
- 1999-09-09 PL PL347073A patent/PL196668B1/pl unknown
- 1999-09-09 CZ CZ20010880A patent/CZ301341B6/cs not_active IP Right Cessation
- 1999-09-09 AT AT99948196T patent/ATE285774T1/de active
- 1999-09-09 CA CA002342390A patent/CA2342390C/fr not_active Expired - Lifetime
- 1999-09-09 AU AU60364/99A patent/AU744071B2/en not_active Revoked
- 1999-09-09 AR ARP990104545A patent/AR022085A1/es active IP Right Grant
- 1999-09-09 WO PCT/US1999/020968 patent/WO2000013687A2/fr active Application Filing
- 1999-09-09 RU RU2001109432/14A patent/RU2207856C2/ru active
- 1999-09-09 PT PT99968627T patent/PT1109558E/pt unknown
- 1999-09-09 JP JP2000568494A patent/JP3745621B2/ja not_active Expired - Lifetime
- 1999-09-09 UA UA2001031623A patent/UA67793C2/uk unknown
- 1999-09-09 DK DK99948196T patent/DK1096937T3/da active
- 1999-09-09 MX MXPA01002598A patent/MXPA01002598A/es active IP Right Grant
- 1999-09-09 EP EP99948196A patent/EP1096937B9/fr not_active Expired - Lifetime
- 1999-09-09 DE DE122008000065C patent/DE122008000065I1/de active Pending
- 1999-09-09 TR TR2001/01262T patent/TR200101262T2/xx unknown
- 1999-09-09 CA CA002343376A patent/CA2343376C/fr not_active Expired - Lifetime
- 1999-09-09 DK DK99968627T patent/DK1109558T3/da active
- 1999-09-09 CZ CZ20010879A patent/CZ301375B6/cs not_active IP Right Cessation
- 1999-09-09 WO PCT/US1999/020967 patent/WO2000013686A2/fr active IP Right Grant
- 1999-09-09 AU AU61425/99A patent/AU760435B2/en not_active Revoked
- 1999-09-09 IL IL14189399A patent/IL141893A0/xx active IP Right Grant
- 1999-09-09 PT PT99948196T patent/PT1096937E/pt unknown
- 1999-09-09 EP EP99968627A patent/EP1109558B1/fr not_active Expired - Lifetime
- 1999-09-09 TR TR2001/01261T patent/TR200101261T2/xx unknown
- 1999-09-09 IL IL14189299A patent/IL141892A0/xx active IP Right Grant
- 1999-09-09 DE DE69901570T patent/DE69901570T2/de not_active Expired - Lifetime
- 1999-09-09 GE GE4322A patent/GEP20053420B/en unknown
- 1999-09-09 EP EP04030151A patent/EP1527779A1/fr not_active Withdrawn
- 1999-09-09 CN CNB998108367A patent/CN1193757C/zh not_active Expired - Lifetime
- 1999-09-09 UA UA2001031622A patent/UA75027C2/uk unknown
- 1999-09-09 PL PL348249A patent/PL196263B1/pl unknown
- 1999-09-09 ES ES99948196T patent/ES2234302T3/es not_active Expired - Lifetime
- 1999-09-09 NZ NZ510384A patent/NZ510384A/xx not_active IP Right Cessation
- 1999-09-09 BR BR9913626-0A patent/BR9913626A/pt not_active Application Discontinuation
- 1999-09-09 AT AT99968627T patent/ATE217794T1/de active
- 1999-09-09 SI SI9930078T patent/SI1109558T1/xx unknown
- 1999-09-09 HU HU0104088A patent/HUP0104088A3/hu unknown
- 1999-09-09 ES ES99968627T patent/ES2177346T3/es not_active Expired - Lifetime
- 1999-09-09 NZ NZ510386A patent/NZ510386A/en not_active IP Right Cessation
- 1999-09-09 RU RU2001109431/14A patent/RU2214233C2/ru active Protection Beyond IP Right Term
- 1999-09-09 KR KR10-2001-7003126A patent/KR100475759B1/ko not_active IP Right Cessation
- 1999-09-09 DE DE69922964T patent/DE69922964T2/de not_active Expired - Lifetime
- 1999-09-09 PL PL381164A patent/PL202207B1/pl unknown
- 1999-09-09 SI SI9930749T patent/SI1096937T1/xx unknown
- 1999-09-09 CN CNB998108359A patent/CN1211086C/zh not_active Expired - Lifetime
- 1999-09-09 HU HU0103844A patent/HU224215B1/hu active Protection Beyond IP Right Term
- 1999-09-09 MX MXPA01002599A patent/MXPA01002599A/es active IP Right Grant
- 1999-09-09 BR BR9913553-1A patent/BR9913553A/pt not_active Application Discontinuation
-
2000
- 2000-03-29 US US09/538,337 patent/US6369062B1/en not_active Expired - Lifetime
- 2000-05-30 TW TW088115657A patent/TWI241911B/zh not_active IP Right Cessation
-
2001
- 2001-03-07 IL IL141893A patent/IL141893A/en not_active IP Right Cessation
- 2001-03-07 IL IL141892A patent/IL141892A/en not_active IP Right Cessation
- 2001-03-08 NO NO20011192A patent/NO320986B1/no not_active IP Right Cessation
- 2001-03-08 NO NO20011191A patent/NO319434B1/no not_active IP Right Cessation
- 2001-08-09 US US09/925,871 patent/US6525057B2/en not_active Expired - Lifetime
- 2001-10-19 US US10/041,521 patent/US6503911B2/en not_active Expired - Lifetime
-
2002
- 2002-03-08 HK HK02101777A patent/HK1040060A1/xx not_active IP Right Cessation
- 2002-08-10 HK HK02105856.0A patent/HK1044284B/zh not_active IP Right Cessation
- 2002-09-25 US US10/254,707 patent/US6562826B1/en not_active Expired - Lifetime
- 2002-09-27 US US10/259,143 patent/US6617328B2/en not_active Expired - Lifetime
- 2002-09-27 US US10/256,993 patent/US6620814B2/en not_active Expired - Lifetime
-
2003
- 2003-03-05 US US10/382,266 patent/US6852724B2/en not_active Expired - Lifetime
- 2003-07-07 US US10/614,460 patent/US6864258B2/en not_active Expired - Lifetime
- 2003-07-07 US US10/614,420 patent/US20040097514A1/en not_active Abandoned
-
2004
- 2004-10-21 US US10/969,891 patent/US20050059667A1/en not_active Abandoned
-
2005
- 2005-01-06 US US11/031,220 patent/US20050153982A1/en not_active Abandoned
- 2005-09-07 US US11/221,450 patent/US20060147521A1/en not_active Abandoned
- 2005-09-20 NO NO20054324A patent/NO20054324L/no unknown
- 2005-10-11 JP JP2005296674A patent/JP2006096757A/ja active Pending
- 2005-11-02 US US11/265,536 patent/US20060217397A1/en not_active Abandoned
-
2006
- 2006-02-24 AR ARP060100699A patent/AR053440A2/es not_active Application Discontinuation
- 2006-02-24 AR ARP060100700A patent/AR052921A1/es not_active Application Discontinuation
- 2006-05-01 IL IL175371A patent/IL175371A0/en unknown
-
2007
- 2007-01-22 IL IL180864A patent/IL180864A0/en unknown
-
2008
- 2008-09-03 AU AU2008207703A patent/AU2008207703A1/en active Pending
- 2008-09-03 AU AU2008207707A patent/AU2008207707A1/en active Pending
- 2008-11-27 NL NL300371C patent/NL300371I2/nl unknown
- 2008-12-03 LU LU91504C patent/LU91504I2/fr unknown
- 2008-12-30 CY CY2008020C patent/CY2008020I2/el unknown
-
2009
- 2009-01-05 FR FR09C0001C patent/FR09C0001I2/fr active Active
- 2009-03-05 NO NO2009005C patent/NO2009005I1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2343376A1 (fr) | Formulations de ranolazine a liberation lente | |
CA2402222A1 (fr) | Formulations de ranolazine a liberation prolongee | |
WO1997045091A3 (fr) | Formulations d'oxycodone a liberation prolongee sans effet sur l'etat alimente/a jeun | |
WO2002045684A3 (fr) | Composition pharmaceutique a dispersion rapide | |
AU2002229573A1 (en) | Pharmaceutical formulation containing pyrazolo(4,3-D)pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives | |
CA2112014A1 (fr) | Composition antiallergique pour usage ophtalmique ou nasal | |
CA2258841A1 (fr) | Granules destines a la preparation de compositions a haut pouvoir de desintegration et de dissolution, a teneur elevee en medicament | |
ZA912793B (en) | Pharmaceutical formulations | |
CA2177772A1 (fr) | Compositions pharmaceutiques renfermant de l'irbesartan | |
CA2334730A1 (fr) | Nouvelles cyclosporines | |
CA2164776A1 (fr) | Composition pharmaceutique, administrable par voie orale | |
MD872G2 (ro) | Compoziţie farmaceutică efervescentă şi preparat pe baza ei, procedeu de fabricare a preparatului | |
HUP0002902A3 (en) | 3-substituted 3,4 dyhydro-thieno[2,3-d]pyrimidine derivatives and their use for the preparation of pharmaceutical compositions | |
CA2231194A1 (fr) | Preparation pharmaceutique | |
AU7588696A (en) | Pyrido{2, 3-D} pyrimidine derivatives and pharmaceutical compositions thereof | |
CA2338794A1 (fr) | Nouvelle formulation orale d'agonistes ou d'antagonistes de 5-ht4 | |
GR1002907B (el) | Επικαλυμμενο δισκιο μηλεινικης τριμεβουτινης | |
CA2176223A1 (fr) | Formulations a base de fenbendazole | |
AU3669700A (en) | 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient | |
HK1045937A1 (en) | Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof | |
IE893578L (en) | Phenyloxypropanolamine derivatives, their preparation and¹their application in therapeutics | |
AU7191891A (en) | Water soluble salts of purpuromycin and pharmaceutical formulations thereof | |
WO1999066902A8 (fr) | Formulations pharmaceutiques injectables de derives de la partricine | |
CA2223014A1 (fr) | Formulation a liberation controlee presentant un passage preforme | |
CA2223259A1 (fr) | Formulations pharmaceutiques a base de derives hautement lipophiles de la camptothecine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20190909 |